The immunomodulatory effect of antibiotics on the secretion of tumour necrosis factor alpha by peripheral blood mononuclear cells in response to Stenotrophomonas maltophilia stimulation

West Indian Medical Journal

Volumn 55, Issue 3, 2006, Pages 138-141

  Vickers, I E ^a   Smikle, M F ^a  

^a UNIVERSITY OF THE WEST INDIES   (Jamaica)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; PIPERACILLIN PLUS TAZOBACTAM; TUMOR NECROSIS FACTOR ALPHA;

ANTIBIOTIC RESISTANCE; ANTIBODY PRODUCTION; ARTICLE; BACTERIAL INFECTION; CELL STIMULATION; CONCENTRATION RESPONSE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; MULTIDRUG RESISTANCE; PERIPHERAL BLOOD MONONUCLEAR CELL; STENOTROPHOMONAS MALTOPHILIA;

EID: 33749610174     PISSN: 00433144     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0043-31442006000300002     Document Type: Article

References (15)

1. Labro MT. Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy" tales? Clin Microbiol Rev 2000; 13: 615-50.
2. Forsgren A, Riesbeck K. Antibiotics and the immune system. In: Finch RG, Greenwood D, Norrby SR and Whitley RJ, eds. Antibiotic and Chemotherapy. 8th ed. London: Churchill Livingstone; 2003: 101-106.
3. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Eng J Med 2003; 348: 138-50.
4. Gilligan PH, Lum G, Vandamme AR, Whittier S. Burkholderia. Stenotrophomonas, Ralstonia, Brevundimonas, Comamonas, Delftia, Pandoraea, and Acidvorax. In: Murray P, Baron EJ, Jorgensen JA, Pfaller M and Yolken RH, editors. Manual of clinical microbiology. 8th, ed. Washington: ASM press, 2003.
5. Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 1998; 11: 57-80.
6. Dignani MC, Grazziutti M, Anaissie E. Stenotrophomonas maltophilia infections. Sem Resp Crit Care Med 2003; 24: 89-98.
7. Villarino ME, Stevens LE, Schable B, Mayers G, Miller JM. Risk factors for epidemic Xanthomonas maltophilia infection/colonisation in intensive care unit patients. Infect Control Hosp Epidemiol 1992; 13: 201-6.
8. Krueger TS, Clark EA, Nix DE. In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations. Diagn Microbiol Infect Dis 2001; 41: 71-8.
9. Liaw S, Teng L, Hsueh P, Ho S, Luh K. In vitro activities of antimicrobial combinations against clinical isolates of Stenotrophomonas maltophilia. J Formos Med Assoc 2002; 101: 495-501.
10. Kucers A, Bennet NM. Eds. The use of antibiotics- a comprehensive review with clinical emphasis. 4th ed London: William Heinemann Medical Books 1987: 808-817.
11. Williams JD. Non-antimicrobial activities of macrolides. International J of Antimicrob Agents 2001; S89-S91.
12. Schultz MJ, Spelman P, van der Poll T. Erythromycin inhibits Pseudomonas aeruginosa-induced tumour necrosis factor-alpha production in human whole blood. J Antimicrob Chemother 2001; 48: 275-8.
13. Petit JC, Daguet GL, Richard G, Burghoffer B. Influence of ciprofloxacin and piperacillin on interleukin-1 production by murine macrophages. J Antimicrob Chemother 1987; 20: 615-7.
14. Riesbeck K, Forsgren A, Henrikson A, Bredberg A. Ciprofloxacin induces an immunomodulatory stress response in Human T Lymphocytes. Antimicrob Agents Chemother 1998; 42: 1923-30.
15. Schultz MJ, Spelman P, Sebastian Z, van Deventer SJH, van der Poll T. Erythromycin inhibits tumour necrosis factor alpha and interleukin 6 production induced by heat-killed Streptococcus pneumoniae in whole blood. Antimicrob Agents Chemother 1998; 42: 1605-9.